NeoGenomics, Inc. (NEO)
USD 9.38
(5.39%)
USD 9.38
(5.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 269.19 Million USD | -22.59% |
| 2022 | 347.74 Million USD | 17.5% |
| 2021 | 295.96 Million USD | 2921.66% |
| 2020 | -10.48 Million USD | 73.87% |
| 2019 | -40.14 Million USD | -139.17% |
| 2018 | 102.49 Million USD | 10.68% |
| 2017 | 92.6 Million USD | -1.11% |
| 2016 | 93.64 Million USD | 95.26% |
| 2015 | 47.95 Million USD | 290.25% |
| 2014 | -25.2 Million USD | -556.01% |
| 2013 | 5.52 Million USD | -53.54% |
| 2012 | 11.89 Million USD | 98.81% |
| 2011 | 5.98 Million USD | 5.22% |
| 2010 | 5.68 Million USD | 194.87% |
| 2009 | 1.92 Million USD | -29.05% |
| 2008 | 2.71 Million USD | 212.7% |
| 2007 | 869.47 Thousand USD | 108.45% |
| 2006 | 417.11 Thousand USD | 3911.32% |
| 2005 | -10.94 Thousand USD | 90.28% |
| 2004 | -112.54 Thousand USD | -119.92% |
| 2003 | 564.94 Thousand USD | 4079.24% |
| 2002 | 13.51 Thousand USD | 117.51% |
| 2001 | -77.21 Thousand USD | -41413.98% |
| 2000 | -186.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 276.26 Million USD | 2.63% |
| 2024 Q3 | 244.27 Million USD | -2.85% |
| 2024 Q2 | 251.43 Million USD | -8.99% |
| 2023 FY | 269.19 Million USD | -22.59% |
| 2023 Q2 | 320.51 Million USD | -4.24% |
| 2023 Q3 | 299.46 Million USD | -6.57% |
| 2023 Q1 | 334.71 Million USD | -3.75% |
| 2023 Q4 | 269.19 Million USD | -10.11% |
| 2022 Q1 | 307.3 Million USD | 3.83% |
| 2022 Q2 | 328.26 Million USD | 6.82% |
| 2022 Q3 | 345.45 Million USD | 5.24% |
| 2022 Q4 | 347.74 Million USD | 0.66% |
| 2022 FY | 347.74 Million USD | 17.5% |
| 2021 Q1 | -27.95 Million USD | -166.52% |
| 2021 Q2 | 219.46 Million USD | 885.05% |
| 2021 Q3 | 272.25 Million USD | 24.06% |
| 2021 Q4 | 295.96 Million USD | 8.71% |
| 2021 FY | 295.96 Million USD | 2921.66% |
| 2020 Q4 | -10.48 Million USD | 24.38% |
| 2020 Q3 | -13.87 Million USD | 81.59% |
| 2020 Q1 | 67.13 Million USD | 267.25% |
| 2020 FY | -10.48 Million USD | 73.87% |
| 2020 Q2 | -75.34 Million USD | -212.23% |
| 2019 Q2 | -29.97 Million USD | -125.47% |
| 2019 Q1 | 117.69 Million USD | 14.83% |
| 2019 Q3 | -42.48 Million USD | -41.75% |
| 2019 Q4 | -40.14 Million USD | 5.52% |
| 2019 FY | -40.14 Million USD | -139.17% |
| 2018 Q3 | -8.12 Million USD | -106.29% |
| 2018 FY | 102.49 Million USD | 10.68% |
| 2018 Q2 | 129.09 Million USD | 50.34% |
| 2018 Q1 | 85.87 Million USD | -7.27% |
| 2018 Q4 | 102.49 Million USD | 1362.05% |
| 2017 Q3 | 92.85 Million USD | -5.62% |
| 2017 Q4 | 92.6 Million USD | -0.27% |
| 2017 FY | 92.6 Million USD | -1.11% |
| 2017 Q1 | 99.95 Million USD | 6.74% |
| 2017 Q2 | 98.37 Million USD | -1.58% |
| 2016 Q1 | 42.04 Million USD | -12.33% |
| 2016 FY | 93.64 Million USD | 95.26% |
| 2016 Q4 | 93.64 Million USD | 172.09% |
| 2016 Q3 | 34.41 Million USD | -15.1% |
| 2016 Q2 | 40.53 Million USD | -3.59% |
| 2015 Q3 | -24.02 Million USD | -4.87% |
| 2015 Q4 | 47.95 Million USD | 299.66% |
| 2015 Q2 | -22.9 Million USD | -8.23% |
| 2015 Q1 | -21.16 Million USD | 16.05% |
| 2015 FY | 47.95 Million USD | 290.25% |
| 2014 Q3 | -25.99 Million USD | -647.17% |
| 2014 Q2 | 4.75 Million USD | -26.67% |
| 2014 Q4 | -25.2 Million USD | 3.03% |
| 2014 FY | -25.2 Million USD | -556.01% |
| 2014 Q1 | 6.47 Million USD | 17.2% |
| 2013 FY | 5.52 Million USD | -53.54% |
| 2013 Q4 | 5.52 Million USD | 80.42% |
| 2013 Q3 | 3.06 Million USD | -24.79% |
| 2013 Q2 | 4.07 Million USD | -12.99% |
| 2013 Q1 | 4.68 Million USD | -60.65% |
| 2012 FY | 11.89 Million USD | 98.81% |
| 2012 Q1 | 9.26 Million USD | 54.77% |
| 2012 Q4 | 11.89 Million USD | -0.18% |
| 2012 Q2 | 9.57 Million USD | 3.39% |
| 2012 Q3 | 11.92 Million USD | 24.46% |
| 2011 FY | 5.98 Million USD | 5.22% |
| 2011 Q4 | 5.98 Million USD | 13.46% |
| 2011 Q3 | 5.27 Million USD | 22.67% |
| 2011 Q2 | 4.3 Million USD | -2.85% |
| 2011 Q1 | 4.42 Million USD | -22.19% |
| 2010 Q3 | 5.77 Million USD | 35.64% |
| 2010 FY | 5.68 Million USD | 194.87% |
| 2010 Q1 | 4.24 Million USD | 120.11% |
| 2010 Q4 | 5.68 Million USD | -1.54% |
| 2010 Q2 | 4.25 Million USD | 0.31% |
| 2009 Q1 | 2.64 Million USD | -2.79% |
| 2009 FY | 1.92 Million USD | -29.05% |
| 2009 Q2 | 3.56 Million USD | 34.76% |
| 2009 Q3 | -565.77 Thousand USD | -115.89% |
| 2009 Q4 | 1.92 Million USD | 440.95% |
| 2008 Q4 | 2.71 Million USD | 32.69% |
| 2008 Q2 | 1.78 Million USD | 110.51% |
| 2008 Q1 | 848.52 Thousand USD | -2.41% |
| 2008 FY | 2.71 Million USD | 212.7% |
| 2008 Q3 | 2.04 Million USD | 14.71% |
| 2007 Q2 | -869.34 Thousand USD | -591.21% |
| 2007 Q1 | 176.98 Thousand USD | -57.57% |
| 2007 Q4 | 869.47 Thousand USD | 885.21% |
| 2007 FY | 869.47 Thousand USD | 108.45% |
| 2007 Q3 | 88.25 Thousand USD | 110.15% |
| 2006 Q1 | 1.29 Million USD | 11927.7% |
| 2006 Q3 | 1.6 Million USD | 10.73% |
| 2006 Q2 | 1.44 Million USD | 11.95% |
| 2006 Q4 | 417.11 Thousand USD | -74.01% |
| 2006 FY | 417.11 Thousand USD | 3911.32% |
| 2005 Q3 | 1.18 Million USD | 5681.61% |
| 2005 FY | -10.94 Thousand USD | 90.28% |
| 2005 Q1 | -112.95 Thousand USD | -0.37% |
| 2005 Q2 | -21.25 Thousand USD | 81.18% |
| 2005 Q4 | -10.94 Thousand USD | -100.92% |
| 2004 Q3 | 405.06 Thousand USD | 312.21% |
| 2004 FY | -112.54 Thousand USD | -119.92% |
| 2004 Q2 | -190.88 Thousand USD | -128.93% |
| 2004 Q4 | -112.54 Thousand USD | -127.79% |
| 2004 Q1 | 659.86 Thousand USD | 16.8% |
| 2003 Q4 | 564.94 Thousand USD | 1521.54% |
| 2003 Q1 | 272.59 Thousand USD | 1916.5% |
| 2003 FY | 564.94 Thousand USD | 4079.24% |
| 2003 Q2 | -13.83 Thousand USD | -105.08% |
| 2003 Q3 | -39.74 Thousand USD | -187.19% |
| 2002 Q3 | -23.56 Thousand USD | 33.42% |
| 2002 Q2 | -35.39 Thousand USD | -3342.7% |
| 2002 FY | 13.51 Thousand USD | 117.51% |
| 2002 Q1 | -1028.00 USD | 98.67% |
| 2002 Q4 | 13.51 Thousand USD | 157.37% |
| 2001 FY | -77.21 Thousand USD | -41413.98% |
| 2001 Q4 | -77.21 Thousand USD | -24808.39% |
| 2001 Q3 | -310.00 USD | -287.5% |
| 2001 Q1 | -500.00 USD | -168.82% |
| 2001 Q2 | -80.00 USD | 84.0% |
| 2000 Q3 | 24.7 Thousand USD | -7.77% |
| 2000 Q1 | 26.84 Thousand USD | 0.0% |
| 2000 FY | -186.00 USD | 0.0% |
| 2000 Q4 | -186.00 USD | -100.75% |
| 2000 Q2 | 26.78 Thousand USD | -0.21% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 782.325% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 4651.728% |
| Aspira Women's Health Inc. | -331 Thousand USD | 81426.586% |
| Biodesix, Inc. | 34.3 Million USD | -684.653% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 4744.474% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 21757.759% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 21757.759% |
| Bionano Genomics, Inc. | 34.88 Million USD | -671.719% |
| CareDx, Inc | -47.97 Million USD | 661.095% |
| Check-Cap Ltd. | -24.75 Million USD | 1187.377% |
| Castle Biosciences, Inc. | -83.53 Million USD | 422.265% |
| DarioHealth Corp. | -7.54 Million USD | 3666.388% |
| Exact Sciences Corporation | 1.94 Billion USD | 86.191% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 426.031% |
| Guardant Health, Inc. | 220.22 Million USD | -22.233% |
| ICON Public Limited Company | 3.56 Billion USD | 92.439% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 45.502% |
| Illumina, Inc. | 1.21 Billion USD | 77.826% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 5055.051% |
| iSpecimen Inc. | -2.14 Million USD | 12635.543% |
| Standard BioTools Inc. | 46.5 Million USD | -478.831% |
| MDxHealth SA | 18.88 Million USD | -1325.422% |
| 23andMe Holding Co. | -141.37 Million USD | 290.413% |
| Medpace Holdings, Inc. | -103.32 Million USD | 360.523% |
| Myriad Genetics, Inc. | 88.1 Million USD | -205.552% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -76843.591% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 11134.661% |
| Neogen Corporation | 735.62 Million USD | 63.407% |
| Inotiv, Inc. | 382.14 Million USD | 29.559% |
| Natera, Inc. | -200.1 Million USD | 234.527% |
| OpGen, Inc. | 11.89 Million USD | -2163.653% |
| OPKO Health, Inc. | 230.68 Million USD | -16.693% |
| Psychemedics Corporation | 334 Thousand USD | -80496.108% |
| Prenetics Global Limited | -43.33 Million USD | 721.157% |
| Prenetics Global Limited | -43.33 Million USD | 721.157% |
| Precipio, Inc. | -386 Thousand USD | 69838.601% |
| Personalis, Inc. | -8.02 Million USD | 3455.659% |
| RadNet, Inc. | 1.14 Billion USD | 76.563% |
| Sera Prognostics, Inc. | -2.02 Million USD | 13413.106% |
| Sotera Health Company | 2.02 Billion USD | 86.709% |
| Neuronetics, Inc. | 2.79 Million USD | -9524.276% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 1855.174% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 1855.174% |
| Trinity Biotech plc | 63.73 Million USD | -322.353% |
| T2 Biosystems, Inc. | 33.8 Million USD | -696.211% |
| Twist Bioscience Corporation | -192.4 Million USD | 239.911% |
| Exagen Inc. | -12.77 Million USD | 2207.665% |